Tagged with M&A

Sweden AddLife is a Swedish company that acquires and streamlines profitable market-leading niche companies in the field of life science. CEO Kristina Willgård examines the company’s international expansion strategy and the goal of doubling in size in five years, highlights her personal commitment to sustainability, and the challenges facing the laboratory…

Sweden Changing demographics and revolutionary technological advancements are altering the structure of the medtech industry paving the way for Arjo, a global Swedish supplier of medical devices and solutions, to rise up to the challenge. CEO Joacim Lindoff discusses the journey after Arjo’s split from Getinge in 2017, the company’s revived…

Sweden Karo Pharma is a Swedish specialty pharma company that develops and markets products to pharmacies and healthcare providers. CEO Christoffer Lorenzen discusses the company’s growth strategy through acquisitions of trusted well-positioned brands, the challenge of incorporating two similar-sized companies, and his high ambitions for the future of Karo Pharma.  …

Opinion David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in mergers and acquisition (M&A) activities involving companies with artificial intelligence/machine learning platforms and technologies and their application to healthcare companies.   Artificial Intelligence Advances in technologies, an incorporation of entrants from outside the industry and changing consumer…

Spain The global acquisition of GSK’s thrombosis portfolio and subsequent purchase of AstraZeneca’s anaesthesia business have been critical milestones for the maverick South African pharmaceutical outfit Aspen, enabling the company to establish a consolidated presence across Europe, including the opening of the firm’s first-ever Spanish affiliate only two and a half…

Germany Bayer’s latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as the company increasingly looks toward cell and gene therapies to bolster its development pipeline and create transformative biotechnological solutions.   German pharmaceutical company Bayer AG is setting its sights on…

Thailand Peter Streibl, general manager of Takeda Thailand, highlights the importance of emerging markets for Takeda globally, as well as the 50–year long commitment of Takeda to Thailand and Thai patients. Streibl further discusses how the Takeda Thailand team has worked to bring crucial innovative products and solutions in various therapeutic…

Thailand Thanakorn and Lakana Ounpiyodom of AeroCare highlight their unique positioning in the inhaler niche and how they have grown both their portfolio and facilities through strategic M&A. They share their strong interest in delivering the most innovative products in the field to Thai patients, and their wish to expand across…

Pharma Pfizer, in an attempt to bolster its oncology portfolio, is set to acquire Array Biopharma for USD 10.6 billion in the second half of 2019. The deal will give Pfizer access to Array’s cancer treatments which are showing promise in phase III trials and protect it against the looming patent…

France Olivier Laureau, global president of Servier Group, outlines the impact of recent acquisitions, the significance of Servier’s recently-opened commercial subsidiary in the US, the ongoing importance of France to the global group, and Servier’s unique value proposition as a privately-owned R&D-focused company.   The acquisition of Shire products also allowed…

France Philippe Chêne, president of Winncare, highlights the key developments of the group over the past three years – most notably its acquisition of the UK player Mangar Health. Chêne goes on to comment on the French reimbursement and medtech environment, pointing out the strong ambitions of the new administration yet…

Novartis Richard Francis, CEO of Sandoz will step down at the end of the March. The abrupt announcement will fan the flames of rumours that parent company Novartis is planning a spinoff or sale for its generics arm.   This is a multi-year journey which I cannot commit to and therefore…